This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
AT-533
Catalog No. T67836 CAS
908112-37-8
AT-533 is a potent inhibitor of Hsp90 and HSV. AT-533 blocks the HIF-1α/VEGF/VEGFR-2 signaling pathway, leading to suppress tumor growth and angiogenesis. AT-533 also inhibits the activation of the downstream pathways, including Erk1/2, FAK, Akt/mTOR/p70S6K,. AT-533 inhibits the cell migration, invasion, and the tube formation of human umbilical vein endothelial cells (HUVECs).
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
AT-533 is a potent inhibitor of Hsp90 and HSV. AT-533 blocks the HIF-1α/VEGF/VEGFR-2 signaling pathway, leading to suppress tumor growth and angiogenesis. AT-533 also inhibits the activation of the downstream pathways, including Erk1/2, FAK, Akt/mTOR/p70S6K,. AT-533 inhibits the cell migration, invasion, and the tube formation of human umbilical vein endothelial cells (HUVECs).
In vitro
AT-533 (0-1350 nM; 24h or 48h) inhibits 20ng/mL VEGF induced tube formation, cell migration and HUVEC invasion. AT-533 (2 μ M or 75 μ M; 24 h) inhibits HIF-1 α/ VEGF in hypoxia induced breast cancer cells signaling pathway and inhibits Akt/mTOR/p70S6K, Erk1/2, and FAK phosphorylation. AT-533 (10 nM, 50 nM; 48 h) exhibits anti angiogenic ability on the chorionic villus (CAM) model [1]. AT-533 (0.5 μ M; 2 hours, 4 hours) reduces TNF induced by HSV-1 in RAW264.7 and BV2 cells- α、 IL-1 β and the production of IL-6 [2].
In vivo
AT-533 (10 mg/kg; intraperitoneal injection; once a day for 21 days) inhibited the expression of HIF-1 α/ VEGF signaling pathway related proteins in mouse MDA-MB-231 xenograft model of breast cancer [1]. AT-533 (1, 2, 4 mg/kg; intraperitoneal injection; once a day for 30 days) did not cause death, appetite loss, weight loss, or adverse reactions in subacute toxicity tests of Sprague Dawley rats [3].
Molecular Weight
410.51
Formula
C23H30N4O3
CAS No.
908112-37-8
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.